October 22, 2019
CheckMate -9LA, a Phase 3 Opdivo study met goals
Bristol-Myers Squibb study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
October 22, 2019
Novartis increses net sales. Net income $2B
Novartis has ended third quarter 2019 with reported net income of $2.0 billion, which as an 8% increase, driven by higher operating income and higher income from associated companies, saying in the press release Tuesday that its EPS was USD 0.90 (+11%, +14% cc), growing faster than net income driven by lower weighted average number of shares outstanding.
October 22, 2019
Bicycle Therapeutics expands neuroscience collaborations with Oxford University’s Oxford Drug Discovery Institute
Bicycle is going to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer’s disease and…
October 22, 2019
Takeda gets license for Celiac Disease therapy from COUR Pharmaceuticals after positive phase 2a proof-of-concept study
Takeda got exclusive global license for investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in…
October 21, 2019
FDA approves AstraZenecas Farxiga for reducing hospitalisation for heart failure in type 2 diabetes patients
AstraZeneca on Monday said that that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
October 21, 2019
Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer meets primary and secondary endpoints
Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer has met primary and secondary endpoints, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, and the company is planning NDA Submission to U.S. FDA for first quarter of 2020.
October 21, 2019
FDA approves Trikafta for treating cause of cystic fibrosis in certain patients
Vertex Pharmaceuticals received FDA’s approval for Trikafta (elexacaftor/tezacaftor/ivacaftor), for treating cystic fibrosis in patients older than 12, who have at…
October 21, 2019
Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation
PARSIPPANY, N.J. & JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. and its affiliates today announced a settlement agreement with both Cuyahoga and…
October 21, 2019
Spanish Government Approves National Reimbursement of Orkambi and Symekevi in Combination With Kalydeco
LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of…
October 21, 2019
Distributors Reach Settlement With Ohio Counties in Opioids Case
CLEVELAND–(BUSINESS WIRE)–AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced this morning that they have agreed to…